Cargando…

Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan

BACKGROUND: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. METHODS: We enrolled 59 RA patients treated with abatacept from a multicenter, exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashiri, Shin-ya, Endo, Yushiro, Nishino, Ayako, Okamoto, Momoko, Tsuji, Sosuke, Takatani, Ayuko, Shimizu, Toshimasa, Sumiyoshi, Remi, Koga, Tomohiro, Iwamoto, Naoki, Ichinose, Kunihiro, Tamai, Mami, Nakamura, Hideki, Origuchi, Tomoki, Aramaki, Toshiyuki, Ueki, Yukitaka, Yoshitama, Tamami, Eiraku, Nobutaka, Matsuoka, Naoki, Okada, Akitomo, Fujikawa, Keita, Hamada, Hiroaki, Nagano, Shuji, Tada, Yoshifumi, Kawakami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171043/
https://www.ncbi.nlm.nih.gov/pubmed/34074293
http://dx.doi.org/10.1186/s12891-021-04392-5
_version_ 1783702354954027008
author Kawashiri, Shin-ya
Endo, Yushiro
Nishino, Ayako
Okamoto, Momoko
Tsuji, Sosuke
Takatani, Ayuko
Shimizu, Toshimasa
Sumiyoshi, Remi
Koga, Tomohiro
Iwamoto, Naoki
Ichinose, Kunihiro
Tamai, Mami
Nakamura, Hideki
Origuchi, Tomoki
Aramaki, Toshiyuki
Ueki, Yukitaka
Yoshitama, Tamami
Eiraku, Nobutaka
Matsuoka, Naoki
Okada, Akitomo
Fujikawa, Keita
Hamada, Hiroaki
Nagano, Shuji
Tada, Yoshifumi
Kawakami, Atsushi
author_facet Kawashiri, Shin-ya
Endo, Yushiro
Nishino, Ayako
Okamoto, Momoko
Tsuji, Sosuke
Takatani, Ayuko
Shimizu, Toshimasa
Sumiyoshi, Remi
Koga, Tomohiro
Iwamoto, Naoki
Ichinose, Kunihiro
Tamai, Mami
Nakamura, Hideki
Origuchi, Tomoki
Aramaki, Toshiyuki
Ueki, Yukitaka
Yoshitama, Tamami
Eiraku, Nobutaka
Matsuoka, Naoki
Okada, Akitomo
Fujikawa, Keita
Hamada, Hiroaki
Nagano, Shuji
Tada, Yoshifumi
Kawakami, Atsushi
author_sort Kawashiri, Shin-ya
collection PubMed
description BACKGROUND: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. METHODS: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. RESULTS: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. CONCLUSION: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. TRIAL REGISTRATION: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-021-04392-5.
format Online
Article
Text
id pubmed-8171043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81710432021-06-03 Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan Kawashiri, Shin-ya Endo, Yushiro Nishino, Ayako Okamoto, Momoko Tsuji, Sosuke Takatani, Ayuko Shimizu, Toshimasa Sumiyoshi, Remi Koga, Tomohiro Iwamoto, Naoki Ichinose, Kunihiro Tamai, Mami Nakamura, Hideki Origuchi, Tomoki Aramaki, Toshiyuki Ueki, Yukitaka Yoshitama, Tamami Eiraku, Nobutaka Matsuoka, Naoki Okada, Akitomo Fujikawa, Keita Hamada, Hiroaki Nagano, Shuji Tada, Yoshifumi Kawakami, Atsushi BMC Musculoskelet Disord Research Article BACKGROUND: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. METHODS: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. RESULTS: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. CONCLUSION: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. TRIAL REGISTRATION: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-021-04392-5. BioMed Central 2021-06-01 /pmc/articles/PMC8171043/ /pubmed/34074293 http://dx.doi.org/10.1186/s12891-021-04392-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kawashiri, Shin-ya
Endo, Yushiro
Nishino, Ayako
Okamoto, Momoko
Tsuji, Sosuke
Takatani, Ayuko
Shimizu, Toshimasa
Sumiyoshi, Remi
Koga, Tomohiro
Iwamoto, Naoki
Ichinose, Kunihiro
Tamai, Mami
Nakamura, Hideki
Origuchi, Tomoki
Aramaki, Toshiyuki
Ueki, Yukitaka
Yoshitama, Tamami
Eiraku, Nobutaka
Matsuoka, Naoki
Okada, Akitomo
Fujikawa, Keita
Hamada, Hiroaki
Nagano, Shuji
Tada, Yoshifumi
Kawakami, Atsushi
Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
title Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
title_full Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
title_fullStr Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
title_full_unstemmed Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
title_short Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
title_sort association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (ra): a multicenter, prospective, and observational ra ultrasound cohort study in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171043/
https://www.ncbi.nlm.nih.gov/pubmed/34074293
http://dx.doi.org/10.1186/s12891-021-04392-5
work_keys_str_mv AT kawashirishinya associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT endoyushiro associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT nishinoayako associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT okamotomomoko associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT tsujisosuke associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT takataniayuko associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT shimizutoshimasa associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT sumiyoshiremi associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT kogatomohiro associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT iwamotonaoki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT ichinosekunihiro associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT tamaimami associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT nakamurahideki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT origuchitomoki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT aramakitoshiyuki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT uekiyukitaka associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT yoshitamatamami associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT eirakunobutaka associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT matsuokanaoki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT okadaakitomo associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT fujikawakeita associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT hamadahiroaki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT naganoshuji associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT tadayoshifumi associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan
AT kawakamiatsushi associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan